Focus on HIV Care

Back to articles

Newly Approved HIV Drugs Reduce Pill Burden

KEY POINT

Two new medications—a protease inhibitor and a nucleoside reverse transcriptase inhibitor (NRTI)—feature once-daily dosing, an important element in maintaining adherence to complicated antiretroviral regimens. Atazanavir (Reyataz—Bristol-Myers Squibb), dosed once daily with food, will be used in combination with other antiretroviral agents for treatment of patients with HIV-1 infection. Emtricitabine (Emtriva—Gilead) is a once-daily, one-capsule NRTI approved for treatment of HIV-1 infection in adults in combination with other antiretroviral medications.

SOURCES

Reyataz Web site. http://www.reyataz.com

FDA talk paper on Reyataz. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01233.html

Emtriva Web site. http://www.emtriva.com

Raffi F et al. Phase III results for Emtriva. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 14, 2003.